Search

Your search keyword '"Kalbasi, Alireza"' showing total 27 results
Start Over Author "Kalbasi, Alireza"
27 results on '"Kalbasi, Alireza"'

2. Radiobiological effects of wound fluid on breast cancer cell lines and human-derived tumor spheroids in 2D and microfluidic culture

Author

Jeibouei, Shabnam, Hojat, Ali, Mostafavi, Ebrahim, Aref, Amir Reza, Kalbasi, Alireza, Niazi, Vahid, Ajoudanian, Mohammad, Mohammadi, Farzaneh, Saadati, Fariba, Javadi, Seyed Mohammadreza, Shams, Forough, Moghaddam, Maryam, Karami, Farshid, Sharifi, Kazem, Moradian, Farid, Akbari, Mohammad Esmaeil, and Zali, Hakimeh

Published
2022
Full Text
View/download PDF

4. Nanoliposomes as nonviral vectors in cancer gene therapy.

Author

Yildiz, Safiye Nur, Entezari, Maliheh, Paskeh, Mahshid Deldar Abad, Mirzaei, Sepideh, Kalbasi, Alireza, Zabolian, Amirhossein, Hashemi, Farid, Hushmandi, Kiavash, Hashemi, Mehrdad, Raei, Mehdi, Goharrizi, Mohammad Ali Sheikh Beig, Aref, Amir Reza, Zarrabi, Ali, Ren, Jun, Orive, Gorka, Rabiee, Navid, and Ertas, Yavuz Nuri

Subjects
CANCER genes, GENE therapy, CANCER treatment, GENETIC vectors, LIPOSOMES, GENETIC carriers
Abstract

Nonviral vectors, such as liposomes, offer potential for targeted gene delivery in cancer therapy. Liposomes, composed of phospholipid vesicles, have demonstrated efficacy as nanocarriers for genetic tools, addressing the limitations of off‐targeting and degradation commonly associated with traditional gene therapy approaches. Due to their biocompatibility, stability, and tunable physicochemical properties, they offer potential in overcoming the challenges associated with gene therapy, such as low transfection efficiency and poor stability in biological fluids. Despite these advancements, there remains a gap in understanding the optimal utilization of nanoliposomes for enhanced gene delivery in cancer treatment. This review delves into the present state of nanoliposomes as carriers for genetic tools in cancer therapy, sheds light on their potential to safeguard genetic payloads and facilitate cell internalization alongside the evolution of smart nanocarriers for targeted delivery. The challenges linked to their biocompatibility and the factors that restrict their effectiveness in gene delivery are also discussed along with exploring the potential of nanoliposomes in cancer gene therapy strategies by analyzing recent advancements and offering future directions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools

Author

Hasanzadeh, Akbar, primary, Ebadati, Arefeh, additional, Dastanpour, Lida, additional, Aref, Amir R., additional, Sahandi Zangabad, Parham, additional, Kalbasi, Alireza, additional, Dai, Xiaofeng, additional, Mehta, Geeta, additional, Ghasemi, Amir, additional, Fatahi, Yousef, additional, Joshi, Suhasini, additional, Hamblin, Michael R., additional, and Karimi, Mahdi, additional

Published
2023
Full Text
View/download PDF

11. Biological impact and therapeutic perspective of targeting PI3K/Akt signaling in hepatocellular carcinoma: Promises and Challenges

Author

Paskeh, Mahshid Deldar Abad, primary, Ghadyani, Fatemeh, additional, Hashemi, Mehrdad, additional, Abbaspour, Alireza, additional, Zabolian, Amirhossein, additional, Javanshir, Salar, additional, Razzazan, Mehrnaz, additional, Mirzaei, Sepideh, additional, Entezari, Maliheh, additional, Goharrizi, Mohammad Ali Shekhi Beig, additional, Salimimoghadam, Shokooh, additional, Aref, Amir Reza, additional, Kalbasi, Alireza, additional, Rajabi, Romina, additional, Rashidi, Mohsen, additional, Taheriazam, Afshin, additional, and Sethi, Gautam, additional

Published
2023
Full Text
View/download PDF

13. 611 Biodistribution and shedding analysis following treatment with RP1 oncolytic immunotherapy in the skin cancer patients from the IGNYTE clinical trial

Author

Milhem, Mohammed, primary, VanderWalde, Ari, additional, Bowles, Tawnya, additional, Sacco, Joseph, additional, Olsson-Brown, Anna, additional, Niu, Jiaxin, additional, Tsai, Katy, additional, Chesney, Jason, additional, Chmielowski, Bartosz, additional, Samson, Adel, additional, Rhodes, Terence, additional, In, Gino, additional, Pavlick, Anna, additional, Wise-Draper, Trisha, additional, Sanmamed, Miguel, additional, Kalbasi, Alireza, additional, Love, Colin, additional, Clack, Aaron, additional, Hou, Jeannie, additional, Bommareddy, Praveen, additional, Coffin, Robert, additional, Middleton, Mark, additional, and Harrington, Kevin, additional

Published
2022
Full Text
View/download PDF

16. Effects of Wound Fluid on Breast Cancer-derived Spheroids in a 3D Culture System: A Case Series Study

Author

Hojat, Ali, primary, Jeibouei, Shabnam, additional, Aref, Amir Reza, additional, Kalbasi, Alireza, additional, Moghaddam, Maryam, additional, Mohammadi, Farzaneh, additional, Javadi, Seyed Mohammadreza, additional, Ajoudanian, Mohammad, additional, Sharifi, Kazem, additional, Zali, Hakimeh, additional, and Akbari, Mohammad Esmaeil, additional

Published
2021
Full Text
View/download PDF

18. TLR Stimulation Produces IFN-β as the Primary Driver of IFN Signaling in Nonlymphoid Primary Human Cells

Author

Nistler, Ryan, primary, Sharma, Ankur, additional, Meeth, Katrina, additional, Huard, Christine, additional, Loreth, Christine, additional, Kalbasi, Alireza, additional, Tyminski, Edyta, additional, Bellmore, Ryan, additional, Coyle, Anthony J., additional, Gullà, Stefano V., additional, Berasi, Stephen P., additional, Greenberg, Steven A., additional, and Buhlmann, Janet E., additional

Published
2020
Full Text
View/download PDF

19. Effects of Wound Fluid on Breast Cancer-derived Spheroids in a 3D Culture System: A Case Series Study.

Author

Hojat, Ali, Jeibouei, Shabnam, Aref, Amir Reza, Kalbasi, Alireza, Moghaddam, Maryam, Mohammadi, Farzaneh, Javadi, Seyed Mohammadreza, Ajoudanian, Mohammad, Sharifi, Kazem, Zali, Hakimeh, and Akbari, Mohammad Esmaeil

Subjects
MICROFLUIDIC devices, TUMOR microenvironment, EXTRACELLULAR matrix, SURGICAL site, BREAST tumors, BREAST
Abstract

Surgery is the standard treatment for breast malignancies, although local and distant relapses might occur. Previous studies have shown that surgery-induced wound fluid (WF) contains tumor-initiating and progressing factors; however, these experiments have only been performed on breast cancer cell lines. Since a cancerous tumor includes various components like malignant cells, recruited non-malignant cells and extracellular matrix, those investigations that only focused on cancer cell lines themselves are not adequate to establish WF's effects. We conducted a 3D model study where we mimicked the tumor microenvironment to re-assess previous in-vitro findings. We generated human-derived breast tumor spheroids from 23 patient specimens, dissociated and cultured them in microfluidic devices. The spheroids from each sample were treated with the patients' WF or RPMI medium. The proportion of live and dead cells was assessed using live/dead assays and fluorescent imaging on day 6. In 22 samples, the percentage of live cells was significantly higher in the WF-treated group than in the RPMI-treated group. In one sample, we observed an opposite trend. The results were contrary in one of the samples, and we reported that case with more details. We compared the two groups using the 3D culture environment of human-derived tumor spheroids prepared from different microfluidic devices to mimic the tumor environment heterogeneity. Our findings showed that most patients with breast cancer benefit from surgical wound healing. However, removal of the surgical-induced serum may not be a method of inhibiting the tumor in all patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

20. Personalized medicine in breast cancer: pharmacogenomics approaches

Author

Jeibouei,Shabnam, Akbari,Mohammad Esmael, Kalbasi,Alireza, Aref,Amir reza, Ajoudanian,Mohammad, Rezvani,Alireza, and Zali,Hakimeh

Subjects
Pharmacogenomics and Personalized Medicine
Abstract

Shabnam Jeibouei,1 Mohammad Esmael Akbari,2 Alireza Kalbasi,3 Amir Reza Aref,4,5 Mohammad Ajoudanian,6 Alireza Rezvani,7 Hakimeh Zali81Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 3Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; 4Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA; 5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; 6Department of Tissue Engineering and Applied Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 7Department of Hematology, Medical Oncology and Stem Cell Transplantation, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; 8Proteomics Research Centre, Department of Tissue Engineering and Applied Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IranAbstract: Breast cancer is the fifth cause of cancer death among women worldwide and represents a global health concern due to the lack of effective therapeutic regimens that could be applied to all disease groups. Nowadays, strategies based on pharmacogenomics constitute novel approaches that minimize toxicity while maximizing drug efficacy; this being of high importance in the oncology setting. Besides, genetic profiling of malignant tumors can lead to the development of targeted therapies to be included in effective drug regimens. Advances in molecular diagnostics have revealed that breast cancer is a multifaceted disease, characterized by inter-tumoral and intra-tumoral heterogeneity and, unlike the past, molecular classifications based on the expression of individual biomarkers have led to devising novel therapeutic strategies that improve patient survival. In this review, we report and discuss the molecular classification of breast cancer subtypes, the heterogeneity resource, and the advantages and disadvantages of current drug regimens with consideration of pharmacogenomics in response and resistance to treatment.Keywords: breast cancer, personalized medicine, biomarker, pharmacogenomics

Published
2019

21. Treg Conditioning Endows Activated Teff with Suppressor Function in Autoimmune Hepatitis/Autoimmune Sclerosing Cholangitis

Author

Liberal, Rodrigo, Grant, Charlotte R, Muhammed, Yuksel, Graham, Jonathon, Kalbasi, Alireza, Ma, Yun, Heneghan, Michael A, Mieli-Vergani, Giorgina, Vergani, Diego, and Longhi, Maria Serena

Subjects
Adult, Male, Hepatitis, Autoimmune, Young Adult, Adolescent, Cholangitis, Sclerosing, Humans, chemical and pharmacologic phenomena, hemic and immune systems, Female, Child, T-Lymphocytes, Regulatory, Article
Abstract

Imbalance between T regulatory (Treg) and T effector (Teff) cells is likely to contribute to the induction and perpetuation of liver damage in autoimmune hepatitis (AIH) and autoimmune sclerosing cholangitis (AISC) either through inability of Tregs to restrain proliferation and effector cytokine production by responders or through conversion of Tregs into T helper type 1 (Th1) or type 17 (Th17) effector lymphocytes. We investigated the effect of Treg skewing on the phenotypic and functional properties of CD4Treg skewing confers activated Teff phenotypic and functional properties of T regulatory 1 cells in health and in AIH/AISC, though suppressive function is lost in patients upon proinflammatory challenge; protracted modulation of the inflammatory environment is required to attenuate the effector potential while boosting immunoregulatory properties in Teff. (Hepatology 2017;66:1570-1584).

Published
2017

22. Optical assays based on colloidal inorganic nanoparticles

Author

Ghasemi, Amir, primary, Rabiee, Navid, additional, Ahmadi, Sepideh, additional, Hashemzadeh, Shabnam, additional, Lolasi, Farshad, additional, Bozorgomid, Mahnaz, additional, Kalbasi, Alireza, additional, Nasseri, Behzad, additional, Shiralizadeh Dezfuli, Amin, additional, Aref, Amir Reza, additional, Karimi, Mahdi, additional, and Hamblin, Michael R., additional

Published
2018
Full Text
View/download PDF

23. Bilirubin suppresses Th17 immunity in colitis by upregulating CD39

Author

Longhi, Maria Serena, primary, Vuerich, Marta, additional, Kalbasi, Alireza, additional, Kenison, Jessica E., additional, Yeste, Ada, additional, Csizmadia, Eva, additional, Vaughn, Byron, additional, Feldbrugge, Linda, additional, Mitshuhashi, Shuji, additional, Wegiel, Barbara, additional, Otterbein, Leo, additional, Moss, Alan, additional, Quintana, Francisco J., additional, and Robson, Simon C., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results